Population Pharmacokinetics/Pharmacodynamics of Carbapenems in Febrile Neutropenia Patients

Inclusion Criteria: 1. Age ≥18 years old, regardless of gender; 2. Patients with malignant hematological diseases with neutropenia and fever are judged as high-risk patients according to the Guidelines for Clinical Application of Antibiotics in Patients with Neutropenia and Fever in China (2020 Edition); 3. There is infection, and the results of drug sensitivity test show that pathogenic bacteria are sensitive to meropenem or meropenem is used according to experience; 4. The blood concentration of meropenem has reached a steady state; 5. Each patient's blood sample points ≥2, and cases with only one blood sample point can also be included in the database; 6. Sign the informed consent form. Exclusion Criteria: 1. Patients with non-malignant hematological diseases; 2. Non-granular deficiency with fever; 3. Those who did not reach steady state when receiving meropenem; 4. There is a history of meropenem drug allergy; 5. The patient lacks treatment compliance based on the patient's history and the judgment of the researcher; 6. The patient has hemophagocytic syndrome; 7. Patients undergoing renal replacement therapy; 8. Patients with incomplete clinical evaluation data (such as lack of information on renal function and biochemical indicators, and inability to obtain blood samples); 9. The sample contains components that interfere with the determination of drug concentration (such as valproic acid and chloramphenicol); 10. Pregnant and lactating women; 11. Cases considered by the researcher as unsuitable for inclusion.